02:35 PM EDT, 04/26/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price by $13 to $125, reflecting a 13.5x multiple of enterprise value to projected 2024 EBITDA, in line with ITGR's historical forward average. We lower our 2024 EPS estimate to $5.30 from $5.33 and raise 2025's to $6.08 from $6.00. ITGR reported Q1 EPS of $1.14 vs. $0.87, exceeding the S&P Capital IQ consensus estimate by $0.03, driven by strong year-over-year growth in Advanced Surgical, Orthopedics, & Portable Medical (+21%) and Cardio & Vascular sales (+9.3%) due to strong demand, acquisition performance, and new product ramps. ITGR reiterated its 2024 guidance, with revenues expected to increase by 10% Y/Y to $1.75 billion at the midpoint, while adjusted earnings are expected to be in the range of $5.01-$5.43 per share (vs. $4.67 per share in 2023). In addition, ITGR expects 2024 free cash flow to be in the range of $95 million (vs. $60 million in 2023), which we expect will be used to pay down debt (net debt stood at $1.1 billion at the end of Q1).